EBC-46 An outstanding candidate for a human anti-cancer treatment
EBC-46 is a novel and highly potent, short-chain diterpene ester in development for local treatment of
solid tumours.
Potential indications for the drug include:
- Skin cancers including Melanomas, Squamous Cell Carcinomas (SCC) & Basal Cell Carcinomas (BCC)
- Head & neck cancers
- Breast cancers
- Prostate cancers
- Other tumours where injection can be guided by imaging
Although only in late pre-clinical development for the human market, QBiotics has already demonstrated very compelling proof-of-concept of the drug’s efficacy and safety both in cancer models in mice and in successful treatment of advanced, spontaneous tumours in dogs, cats and horses that were considered untreatable with current standards of care. Few, if any, oncology drugs at a similar pre-clinical stage of development have such convincing proof-of-concept of efficacy in treating a wide range of tumour types in diverse patient populations with no apparent side effects.
In addition, the mode of action of the EBC-46 drug class has been demonstrated to be both safe and effective in humans through the development of Peplin’s compound PEP005 successfully into Clinical Phase III
(for a pre-cancerous skin condition) and thus the potential for successful clinical development of EBC-46 is
extremely high.